Has Nauveed Iqbal, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,213 in general payments to Nauveed Iqbal, MD across 99 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nauveed Iqbal, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nauveed Iqbal, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nauveed Iqbal, MD

Surgery · Bridgeton, NJNPI 1104851492

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $496 and has fallen 89.0% since, to $55 in 2025.

$2,213in general payments, 2019–2025

Across 99 payments — averaging $22.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$413
Smith+Nephew$369
Mozarc Medical US LLC$164
AbbVie$148
Johnson & Johnson$136
Davol Inc.$106
plus $877 from 22 others

What the payments were for

Food & beverage$2,213100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	22	$413
Smith+Nephew	10	$369
Mozarc Medical US LLC	3	$164
AbbVie	2	$148
Johnson & Johnson(2 entities)	8	$136
Davol Inc.	5	$106
Endo Pharmaceuticals Inc.	7	$103
Baxter Healthcare	3	$73
Integra Lifesciences Corporation	3	$72
Medtronic(2 entities)	4	$63
TELA Bio, Inc.	2	$58
Kowa Pharmaceuticals America, Inc.	4	$55
Biom'up France SAS	2	$46
Abbott	3	$45
Lemaitre Vascular, Inc.	1	$44
Misonix Inc	2	$34
Teleflex LLC	2	$32
Covidien LP	2	$32
Mannkind Corporation	2	$29
Cashflow Solutions, LLC	2	$28
Kerecis Limited	2	$27
Bard Peripheral Vascular, Inc.	1	$25
Eisai Inc.	2	$24
KCI USA, Inc.	1	$23
Cardiovascular Systems Inc.	1	$19
Standard Bariatrics, Inc.	1	$17
Lilly USA, LLC	1	$17
Pacira Pharmaceuticals Incorporated	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,213 in reported general payments places this provider in the 55th percentile of 593 surgery providers in New Jersey.

See all surgery providers in New Jersey →

Medicare billing

Part B allowed, 2024

$193,969

Medicare patients

326

Services billed

1,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Omeprazole	43	$344
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	14	$154
Acetaminophen-CodeineAcetaminophen With Codeine	14	$102

Paid to pharmacies, not to this prescriber.

Other surgery in Bridgeton

Robert PerezHainesport$2M
Eric WhitmanMorristown$848K
Jarrod KaufmanBrick$474K
Amit TrivediParamus$242K
Young HongCamden$203K
Harvey RainvilleGlen Ridge$159K
Harrison CotlerOakhurst$149K
Francis PrevitiNorth Field$131K
David DupreeTinton Falls$124K
Patricia MartzCape May Court House$98K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →